Reselute has filed a notice of an exempt offering of securities to raise $4 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Reselute is raising up to $4 Million in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Reselute
Reselute is a medical technology company focused on developing innovative devices to treat orthopedic-related infections. Based on years of academic research translated into practical solutions, the company designs and develops therapeutic orthopedic devices that deliver antibiotics locally at the site of infection, aiming to accelerate treatment and improve patient care. Its primary business activity centers on creating advanced, load-bearing, bioactive biomaterial implants that provide broad-spectrum antibacterial coverage for challenging musculoskeletal infections associated with orthopedic implants and traumatic injuries. Reselute positions itself as a specialist in orthopedic infection care, working to standardize and improve outcomes in a niche but critical area of surgery and trauma medicine. The company emphasizes the use of cutting-edge biomaterials and localized drug delivery technology to offer first-in-class, one-stage solutions that integrate structural support with targeted infection control.
To learn more, visit https://www.reselutemedical.com/
LinkedIn: https://www.linkedin.com/company/reselute
Contact:
Cambre Kelly, President and Chief Executive Officer
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.